Card image cap
Dr Reddy’s Lab buys Cidmus brand of Novartis in India

India’s leading drug maker Dr. Reddy’s Laboratories said that it has entered into an agreement with Swiss-pharma major Novartis to acquire the cardiovascular brand Cidmus in India for Rs 456 crore ($61 million). Under the agreement, Dr. Reddy’s will be assigned and transferred the Cidmus trademark in India from Novartis. The Cidmus brand is a combination of high blood pressure drug valsartan and antihypertensive drug sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction.

Elevate your practice with our advanced AI-based CDSS Tool.Transform your practice now!

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Submit a Comment